News | Contrast Media | November 04, 2019

The MRI contrast agent Clariscan (gadoterate meglumine) is now FDA approved for injection for intravenous use

The U.S. Food and Drug Administration (FDA) has approved Clariscan, a macrocyclic, ionic, gadolinium-based, magnetic resonance imaging (MRI) contrast agent, expanding the GE Healthcare portfolio

November 4, 2019 – The U.S. Food and Drug Administration (FDA) has approved Clariscan, a macrocyclic, ionic, gadolinium-based, magnetic resonance imaging (MRI) contrast agent, expanding the GE Healthcare portfolio for U.S. patients and radiologists. Clariscan is a gadolinium-based contrast agent indicated for intravenous use with MRI in brain (intracranial), spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Clariscan has been approved in more than 55 countries globally and has had more than four million patient doses shipped in those countries. It is the latest in a growing range of imaging agents available in the U.S. from GE Healthcare. For more than 40 years, GE agents have been routinely used across MRI, X-ray/ computed tomography (CT) and ultrasound to enhance the image and support diagnosis.

“Demand for contrast media has significantly increased over the past decade. The introduction of Clariscan increases our clinical offering for U.S. radiologists, enhancing visualization to provide better patient care. Our customers rely on our high-quality products, first-rate supply network, and surrounding services to support their day-to-day work,” explained Kevin O’Neill, president and CEO Pharmaceutical Diagnostics at GE Healthcare.

“The FDA’s approval of this macrocyclic MR agent adds to the range of contrast media options available here in the U.S. and as radiologists we welcome this broader choice,” said Lawrence N Tanenbaum, M.D., FACR

GE Healthcare offers diagnostic imaging agents used in approximately 90 million procedures per year globally, equivalent to three patients every second. In the U.S., GE Healthcare has a strong record of innovation in new contrast media products and indications, with recent FDA approvals for Omnipaque (iohexol) in CT of the abdomen and for Visipaque (iodixanol) in coronary CT angiography. GE Healthcare has invested $240 million in its global manufacturing and supply network over the past five years to deliver imaging agents to hospitals and pharmacies globally.

Clariscan is manufactured in Norway using a proprietary manufacturing process. As with all GE Healthcare contrast media products, all stages of manufacturing, from development of the active pharmaceutical ingredient (API) to finished product, are managed entirely by GE Healthcare. Clariscan is available in single dose vials of 10, 15 and 20 mL. The packaging contains a 2D data matrix (barcode) on every Clariscan pack, which conveys key information, including national drug code number, individual lot number, and expiration date. This information can be easily scanned and uploaded onto electronic medical systems, helping to reduce the risk of manual data entry errors and helping workflow efficiencies at medical centers. 

For more information: https://corporate.gehealthcare.com/ 

Related content:

VIDEO: Managing Gadolinium Safety

Strategies to Lower CT Contrast Dose and Track Usage

Nurse Injured in MRI Accident at Swedish Hospital

Indian Man Killed in MRI Accident


Related Content

News | Radiology Business

February 2, 2023 — Five additional imaging centers across Allegheny Health Network (AHN) have been recognized by the ...

Time February 02, 2023
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a recap of what ITN viewers found most interesting during the month of January: 1. A Look at the Changes in 2023 ...

Time February 01, 2023
arrow
News | Ultrasound Imaging

January 31, 2023 — Esaote, a leading Italian company in the biomedical sector – in ultrasound, dedicated MRI and medical ...

Time January 31, 2023
arrow
News | Computed Tomography (CT)

January 30, 2023 — Photon-counting detector CT reduces the amount of contrast needed for CT angiography (CTA) while ...

Time January 30, 2023
arrow
News | Digital Pathology

January 27, 2023 — Fujifilm has completed its asset purchase of Inspirata, Inc.’s digital pathology business effective ...

Time January 27, 2023
arrow
Videos | PACS

Konica Minolta Healthcare recently announced it is working with Amazon Web Services to offer its cloud-based Exa ...

Time January 27, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

January 25, 2023 — On November 11th, 2022 at the Southern Hills Hospital in Las Vegas, USA, Robotic Spine Surgeon Dr ...

Time January 25, 2023
arrow
Feature | Enterprise Imaging

The Imaging Technology News (ITN) team was saddened to hear of the untimely passing of Frank Pecaitis, US North American ...

Time January 24, 2023
arrow
Feature | Radiology Imaging | By Melinda Taschetta-Millane

Have you read the January/February 2023 issue of Imaging Technology News? If not, take some time out of your busy ...

Time January 24, 2023
arrow
News | Digital Radiography (DR)

January 24, 2023 — Carestream Health was awarded 20 new patents in 2022 for global advances in artificial intelligence ...

Time January 24, 2023
arrow
Subscribe Now